A Phase 1 study of KQB198 in advanced solid tumors

Study Description

A study to evaluate the safety and efficacy of KQB198 alone or in combination with other anticancer drugs in patients with advanced solid tumors

Study Details

Registry ID:

NCT06507306

Conditions:

Solid Tumor, Adult

Phase:

Phase 1

Target Enrollment:

92 participants

Start Date:

June 3, 2024

Age Range:

18–999 years

Healthy Volunteers:

No

Study Locations (38 sites)

• Hospital Quirónsalud Málaga
  MalagaSpain, Spain
• South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
  MadridSpain, Spain
• New Experimental Therapeutics (NEXT) Oncology Madrid - Hospital Quironsalud Madrid
  MadridSpain, Spain
• South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC
  MadridSpain, Spain
• Hospital Universitario Ramon y Cajal
  MadridSpain, Spain
• Hospital Universitario Vall d'Hebron
  Barcelona, CataloniaSpain, Spain
• South Texas Accelerated Research Therapeutics (START) Barcelona- HM Nou Delfos
  BarcelonaSpain, Spain
• New Experimental Therapeutics (NEXT) Oncology Barcelona
  BarcelonaSpain, Spain
• Hospital Universitari Quiron Dexeus Barcelona
  Barcelona, CataloniaSpain, Spain
• Clinica Universidad de Navarra - Pamplona
  PamplonaSpain, Spain
• Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
  NaplesItaly, Italy
• Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
  NapoliItaly, Italy
• IUCT-Oncopole
  Toulouse, OccitaineFrance, France
• Institut Paoli-Calmettes
  Marseille, Bouches-du-RhôneFrance, France
• Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
  Roma, LazioItaly, Italy
• Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
  Rome, LazioItaly, Italy
• CHU Bordeaux - Hopital Saint-Andre
  Bordeaux, Nouvelle-AquitaneFrance, France
• Institut de Cancerologie de l'Ouest - site St-Herblain
  Saint-Herblain, Loire-AtlantiqueFrance, France
• CHU de Nantes - Hopital Nord Laennec
  Nantes, Pays De La LoireFrance, France
• CHU de Nantes - Hopital Nord Laennec
  Nantes, Pays de la Loire RegionFrance, France
• David H. Koch Center for Cancer Center at Memorial Sloan Kettering Cancer Center
  Long Island City, New YorkUnited States, United States
• Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona -
  Orlando, FloridaUnited States, United States
• Sarah Cannon Research Institute at Florida Cancer Specialists
  Orlando, FloridaUnited States, United States
• NEXT Oncology
  Fairfax, VirginiaUnited States, United States
• New Experimental Therapeutics of Virginia - NEXT Oncology
  Fairfax, VirginiaUnited States, United States
• Florida Cancer Specialists - Sarasota
  Sarasota, FloridaUnited States, United States
• Florida Cancer Specialists
  Sarasota, FloridaUnited States, United States
• The Lindner Center for Research and Education at The Christ Hospital
  Cincinnati, OhioUnited States, United States
• Henry Ford Health System
  Detroit, MichiganUnited States, United States
• SCRI Oncology Partners
  Nashville, TennesseeUnited States, United States
• Sarah Cannon and HCA Research Institute
  Nashville, TennesseeUnited States, United States
• New Experimental Therapeutics of San Antonio - NEXT Oncology
  San Antonio, TexasUnited States, United States
• NEXT Oncology
  San Antonio, TexasUnited States, United States
• Sarah Cannon Research Institute at HealthONE
  Denver, ColoradoUnited States, United States
• Chonnam National University Hwasun Hospital
  Hwasun, Jeollanam-doKorea, Republic of, Korea, Republic of
• National Cancer Center
  Goyang-si, Gyeonggi-doKorea, Republic of, Korea, Republic of
• Seoul St. Mary's Hospital, The Catholic University of Korea
  SeoulKorea, Republic of, Korea, Republic of
• Severance Hospital, Yonsei University Health System
  SeoulKorea, Republic of, Korea, Republic of

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →